Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis

Brittany E Yee, Nghia H Nguyen, Bing Zhang, Derek Lin, Philip Vutien, Carrie R Wong, Glen A Lutchman, Mindie H Nguyen

ABSTRACT

Background: Pegylated interferon and ribavirin (PEG-IFN+RBV) may be more cost-effective than direct-acting antivirals in resource-limited settings. Current literature suggests sustained virological response (SVR) in hepatitis C virus genotype 4 (HCV-4) is similar to genotype 1 (HCV-1), but worse than 2 and 3 (HCV-2/3). However, few studies have compared treatment response between these groups and these have been limited by small sample sizes with heterogeneous designs. We performed a meta-analysis of SVR predictors in HCV-4 versus HCV-1, 2, and 3 patients treated with PEG-IFN+RBV.

Methods: In November 2013, we searched for ‘genotype 4’ in MEDLINE/EMBASE databases and scientific conferences. We included original articles with ≥25 treatment-naïve HCV-4 and comparisons to HCV-1, 2, and/or 3 patients treated with PEG-IFN+RBV. Random effects modelling was used with heterogeneity defined by Cochrane Q-test (p value<0.10) and I² statistic (>50%).

Results: Five studies with 20 014 patients (899 HCV-4; 12 033 HCV-1; and 7082 HCV-2/3 patients) were included. SVR was 53% (CI 43% to 62%) for HCV-4, 44% (CI 40% to 47%) for HCV-1; and 73% (CI 58% to 84%) for HCV-2/3. SVR with EVR (early virological response) was 75% (CI 61% to 86%) in HCV-4; 64% (CI 46% to 79%) in HCV-1; and 85% (CI 71% to 93%) in HCV-2/3. SVR without EVR was 10% (CI 6% to 17%) for HCV-4; 13% (CI 12% to 15%) for HCV-1; and 23% (CI 16% to 33%) for HCV-2/3.

Conclusions: SVR rates are similar in HCV-4 (~50%) and HCV-1 (~40%). Lack of EVR is a good stopping rule for HCV-4 and HCV-1 since only 10% subsequently achieve SVR. In HCV-4 patients with EVR, three-quarters can expect to achieve SVR with PEG-IFN+RBV.

BACKGROUND

Hepatitis C virus (HCV) is a worldwide health burden affecting approximately 170 million patients globally.1-3 In about 40 000 patients each year, chronic infection leads to progressive liver scarring, end-stage liver disease or hepatocellular carcinoma.4,5 These disease outcomes as well as response to therapy are influenced by HCV genotype.

There are six known HCV genotypes, which are geographically distributed. HCV-1 is the most prevalent worldwide, especially in the USA and Northern Europe, and is
responsible for approximately 70% of the global chronic hepatitis C (CHC) population. In contrast, HCV-4 is more prominent in Africa and the Middle East, comprising up to 80% of the CHC burden in this region.

Most registration trials with interferon-based therapies have been conducted in Western countries where HCV-1, 2, and 3 are prevalent, but data on other genotypes, especially HCV-4, is limited. The goal of HCV treatment is to achieve sustained virological response (SVR), defined as undetectable HCV RNA at 24 weeks after cessation of therapy. While SVR rates have been firmly established in HCV-1, 2 and 3 by landmark clinical trials, the rate of SVR in HCV-4 has been wide-ranging from 28% to 71% based on smaller studies with heterogeneous designs mostly conducted in Africa and Eastern Mediterranean countries.

Guidelines recommend the same 48-week treatment duration with PEG-IFN+RBV for HCV-4 and HCV-1, based on the assumption that these genotypes have similar SVR rates. While some studies comparing HCV-4 and HCV-1 have shown no difference in SVR rates between these genotypes, others have shown a trend favouring higher SVR rates for HCV-4 patients compared to HCV-1 patients. Additional research is needed to better our understanding of HCV-4 and HCV-1 since these two genotypes may be considered as separate entities and ultimately require different treatment considerations.

The aim of our study is to systematically and qualitatively assess treatment predictors and outcomes in studies directly comparing patients with HCV-4 and HCV-1, 2, and/or 3 who were treated with PEG-IFN +RBV.

METHODS

Data sources and searches
In November 2013, we performed a literature search in PubMed filtered for MEDLINE-indexed articles with the search term: ‘(genotype 4)’. Studies in non-English languages were included. We also performed a literature search in EMBASE with the search term: ‘hepatitis c’/exp, and conducted a manual review of abstracts using the search term ‘genotype 4’ for all recent international gastroenterology and liver society meetings held between 2012 and 2013, which included the American Association for the Study of Liver Diseases (AASLD), Asian Pacific Study of the Liver (APASL), Digestive Disease Week (DDW) and European Association for the Study of the Liver (EASL).

Study selection
Inclusion criteria were original studies with a minimum sample size of ≥25 treatment-naïve, HCV-4 and comparison treatment arm of HCV-1, 2, and/or 3 patients, all of whom received treatment with PEG-IFN+RBV. Both prospective controlled trials and retrospective cohort reports were eligible for inclusion. Exclusion criteria were patients coinfected with hepatitis B or D, HIV or other liver diseases. Two of the study authors (BEY and BZ) evaluated the studies independently, and a third author (MHN) re-reviewed these articles. Any discrepancies were resolved by consensus.

Data extraction
The study team developed a data abstraction form for this meta-analysis. Information collected from studies were the following: (1) study characteristics including year published, country of origin, study design, study type (randomised-controlled trial vs observational), practice setting (university or community), and intention-to-treat (ITT) analysis; (2) patient characteristics including age, gender, ethnicity, degree of fibrosis, viral load, and ALT level; (3) treatment predictors including length of treatment (24-weeks compared to 48-weeks), rates of rapid virological response (RVR, defined as undetectable HCV RNA at week 4 of treatment) and early virological response (EVR, defined as at least 2-log 10 reduction of HCV RNA from baseline at week 12 of treatment); (4) rates of SVR (SVR, defined as undetectable HCV RNA at 24 weeks after cessation of treatment).

Statistical analysis
Statistical analyses were performed using random effects modelling (DerSimonian and Laird method) and inverse variance method to present pooled event rates (overall SVR rate) with corresponding 95% CIs. Study heterogeneity was assessed using χ²-based Cochrane Q-statistic with p≤0.10 and I²≥50% as per the standards of quality for reporting meta-analysis from the Cochrane handbook. For subgroup analyses, ORs and corresponding 95% CIs were performed. Funnel plots of ln[OR] against SE were performed to evaluate for publication bias. One-way removed influence analysis was conducted to identify potential outliers contributing to our pooled estimates. A fixed value of ‘0.5’ was added to all cells of study results tables in studies with zero-cell counts. Statistical tests were all two sided. All statistical tests were performed using Comprehensive Meta-Analysis, V2 (Biostat, Englewood, New Jersey, USA).

RESULTS

Literature search
As shown in figure 1, a comprehensive literature review of PubMed and EMBASE identified 1798 studies. Review of scientific conferences held in the past 2 years identified 14 648 abstracts. Based on abstract and article titles, a total of 16 446 studies were not relevant and excluded prior to screening. Eighty-four studies were closely reviewed. Eighty-four studies were not relevant; 45 studies did not have direct comparison arms of HCV-1, 2, and/or 3; A total of 79 studies were excluded for the following reasons: 45 studies did not have direct comparison arms of HCV-1, 2, and/or 3; 7, 10–15, 16–31 33–39 41 44 45 47–59 61–93 A total of 79 studies were excluded for the following reasons: 45 studies did not have direct comparison arms of HCV-1, 2, and/or 3; 7, 10–15, 16–31 33–39 41 44 45 47–59 61–93 A total of 79 studies were excluded for the following reasons: 45 studies did not have direct comparison arms of HCV-1, 2, and/or 3; 7, 10–15, 16–31 33–39 41 44 45 47–59 61–93 A total of 79 studies were excluded for the following reasons: 45 studies did not have direct comparison arms of HCV-1, 2, and/or 3; 7, 10–15, 16–31 33–39 41 44 45 47–59 61–93 A total of 79 studies were excluded for the following reasons: 45 studies did not have direct comparison arms of HCV-1, 2, and/or 3; 7, 10–15, 16–31 33–39 41 44 45 47–59 61–93 A total of 79 studies were excluded for the following reasons: 45 studies did not have direct comparison arms of HCV-1, 2, and/or 3; 7, 10–15, 16–31 33–39 41 44 45 47–59 61–93
3 studies included patients coinfected with other conditions, including hepatitis B virus, HIV or other liver diseases; 69 81 83 3 studies did not assess treatment-naïve patients; 64 65 89 2 studies did not contain original data; 74 90 1 study did not meet our minimum sample size requirement of at least 25 HCV patients; 66 1 study did not include patients treated for 48 weeks. 40 A total of five studies met all eligibility criteria and were included in the primary analysis. 14 32 42 43 46

Characteristics of included studies and patients
Five full-length articles with a total of 20,014 patients (899 HCV-4; 12,033 HCV-1; and 7082 HCV-2/3 patients) were included in this meta-analysis (table 1). All were observational or non-randomised. Four studies were prospective 32 42 43 46 while one was retrospective in design. 14 Four of the five studies analysed SVR rates according to ITT. 14 32 42 43 Study origins included two from Kuwait, 14 32 one from Germany 43 and one from Cameroon. 46 One study was conducted in 19 countries. 42 The majority of patients were male. Mean age ranged from 44.5 to 54.3 years for HCV-4; 47.4 to 53 years for HCV-1; and 46.3 to 51.4 years for HCV-2/3. This analysis only included patients treated with PEG-IFN+RBV.

SVR rates by genotype
Based on five studies, pooled SVR rate for HCV-4 was 52.7% (CI 43.4% to 61.9%) (Q-statistic=21.04, p<0.001, I²=80.99%) (table 2). Corresponding pooled SVR rates for HCV-1 and HCV-2/3 were 43.7% (CI 40.3% to 47.1%) (Q-statistic=17.696, p=0.001, I²=77.40%) and 72.9% (CI 58.5% to 83.7%) (Q-statistic=190.997, p<0.001, I²=98.43%), respectively. Statistically significant heterogeneity was found in the analysis of each genotype and this may be attributed to variation in the patient characteristics and methodologies among the included studies.

SVR rates in HCV-4 and HCV-1 were comparable, detecting no statistically significant difference, OR 1.16 (CI 0.92 to 1.48, p=0.21) (Q-statistic=6.264, p=0.18, I²=36.14%). In contrast, the rate of SVR in HCV-2/3 was higher than HCV-4, OR 2.74 (CI 1.55 to 4.85, p=0.01) (Q-statistic=21.046, p<0.001, I²=85.75%) as well as HCV-1, OR 3.33 (CI 1.89 to 5.87, p<0.001) (Q-statistic=90.944, p<0.001, I²=96.70%).

Treatment predictors of SVR by genotype
Rapid virological response
Two studies provided data on RVR for a total of 12,982 patients. 42 43 Pooled rates of RVR were 39.3% (CI 35.3%
to 43.5%) (Q-statistic=0.452, p=0.501, I²=0.00%) in 552 patients with HCV-4; 24.8% (CI 23.9% to 25.8%) (Q-statistic=0.131, p=0.717, I²=0.00%) in 8173 patients with HCV-1; and 75.9% (CI 71.2% to 80.0%) (Q-statistic=1.735, p=0.001, I²=91.48%) in 4257 patients with HCV-2/3.

Direct comparison of RVR rates detected statistically significant differences favouring HCV-2/3 over HCV-4, OR 4.85 (CI 3.40 to 6.94, p<0.001) (Q-statistic=3.732, p=0.053, I²=73.21%), and HCV-4 over HCV-1, OR 1.96 (CI 1.64 to 2.35, p<0.001) (Q-statistic=0.295, p=0.59, I²=0.00%).

Early virological response
In four studies, pooled rates of EVR were 72.8% (CI 63.5% to 80.5%) for 695 patients with HCV-4 and 91.4% (CI 88.8% to 93.4%) for 5568 patients with HCV-2/3. In three studies, pooled rate of EVR was 59.4% (CI 57.9% to 60.9%) for 4178 patients with HCV-1. Direct comparison of EVR rates detected a statistically significant difference favouring HCV-2/3 over HCV-4, OR 3.53 (CI 1.81 to 6.87, p<0.001) (Q-statistic=17.820, p<0.001, I²=83.16%), but did not detect any statistically significant difference between HCV-4 and HCV-1, OR 1.46 (CI 0.88 to 2.43) (Q-statistic=3.119, p=0.21, I²=35.88%).

SVR in patients who achieved EVR
Regarding the rate of SVR in patients who achieved EVR, three studies provided data on HCV-1 and HCV-2/3 while four studies provided data on HCV-4. The pooled rates of SVR in those who achieved EVR were 75.4% (CI 61.4% to 85.6%) in 300 HCV-4 patients; 64% (CI 46.4% to 78.6%) in 2481 HCV-1 patients; and 85.2% (CI 71.8% to 92.9%) in 1876 HCV-2/3 patients. As shown in figure 2, direct comparison of SVR rates detected a statistically significant difference favouring HCV-2/3 over HCV-4 in patients who achieved EVR, OR 2.33 (CI 1.71 to 3.16, p<0.001) (Q-statistic=4.42, p=0.042, I²=57.45%). No statistically significant difference was found between HCV-4 and HCV-1 patients who reached EVR, OR 1.29 (CI 0.52 to 3.19) (Q-statistic=4.701, p=0.095, I²=35.88%).

SVR in patients who did not reach EVR
Regarding the rate of SVR in patients who did not reach EVR, four studies provided data on HCV-4 while three studies provided data on HCV-1 and HCV-2/3. The pooled rates of SVR in those who did not reach EVR were 10% (CI 5.7% to 16.6%) in 127 HCV-4 patients; 13.1% (CI 11.6% to 14.8%) in 1698 HCV-1 patients; and 22.3% (CI 16.6% to 30.2%) in 146 HCV-2/3 patients. As shown in figure 3, direct comparison of SVR rates detected a statistically significant difference favouring HCV-2/3 over HCV-4 in patients who did not reach EVR, OR 2.75 (CI 1.28 to 5.92, p=0.01) (Q-statistic=0.64, p=0.909, I²=0.00%). No statistically significant difference was found between HCV-4 and HCV-1 patients who did
not reach EVR, OR 0.72 (CI 0.37 to 1.43) (Q-statistic=0.178, p=0.915, I²=0.00%).

**DISCUSSION**

In our primary analysis, we included five studies with a total of 20,014 patients (899 HCV-4; 12,033 HCV-1; and 7,082 HCV-2/3). We observed pooled SVR rates of 53%, 44%, and 73% in patients with HCV-4, HCV-1 and HCV-2/3, respectively. While SVR rates with HCV-2/3 patients were significantly higher than HCV-4, we found no statistically significant difference between SVR rates with HCV-1 patients compared to HCV-4.

Prior guidelines from EASL in 201394 and AASLD in 20095 recommended dual therapy with PEG-IFN+RBV for HCV-4 carriers. Both societies’ recommendations for response guided therapy combined recommendations for HCV-4 with HCV-1. Beginning in 2011, telaprevir and boceprevir were the first new direct-acting antivirals (DAA) licensed for use in HCV-1. Currently there are several other DAAs available, including sofosbuvir, simeprevir, sofosbuvir/ledipasvir, and paritaprevir/ritonavir/ombitasvir, which are approved for HCV-1 and HCV-4.95–97 With shorter treatment duration and higher potency, triple therapy has significantly improved virological response rates for many HCV-infected individuals. However, this therapeutic option may remain elusive for patients in developing or under-resourced regions who lack access to DAAs. Therefore, dual therapy with PEG-IFN+RBV will likely remain the mainstay of treatment for many CHC patients in developing countries and is still a treatment option in the WHO guidelines.98

Although societies have grouped HCV-4 with HCV-1, there has been conflicting data as some studies showed a trend towards higher SVR rates in HCV-4 compared to HCV-1,14 32 whereas other studies have not demonstrated any significant differences.42 43 46 In our meta-analysis of studies directly comparing HCV-4 and HCV-1 patients, HCV-4 patients had significantly higher rates of RVR (OR 1.96, CI 1.64 to 2.35, p<0.001), but no statistically significant difference in SVR rates (53% vs 44%, OR 1.16 (CI 0.92 to 1.48, p=0.21)). Additionally, when compared to patients with HCV-2/3, patients with HCV-4 and HCV-1 both had lower rates of RVR, EVR and SVR.

### Table 2  Treatment response in HCV-4 compared to HCV-1 and HCV-2/3

| Treatment response | HCV-4 (n=899) | HCV-1 (n=12,033) | HCV-2/3 (n=7,082) |
|--------------------|---------------|------------------|-------------------|
| SVR                | 53% (CI 43% to 62%) | 44% (CI 40% to 47%) | 73% (CI 58% to 84%) |
| RVR                | 39% (CI 35% to 44%) | 25% (CI 24% to 56%) | 76% (CI 71% to 80%) |
| EVR                | 72% (CI 64% to 81%) | 59% (CI 58% to 61%) | 91% (CI 89% to 93%) |
| +EVR/+SVR          | 75% (CI 61% to 86%) | 64% (CI 46% to 79%) | 85% (CI 71% to 93%) |
| −EVR/+SVR          | 10% (CI 6% to 17%) | 13% (CI 12% to 15%) | 23% (CI 16% to 33%) |

EVR, early virological response; HCV, hepatitis C virus; RVR, rapid virological response; SVR, sustained virological response.

---

Yee BE, Nguyen NH, Zhang B, et al. *BMJ Open Gastroenterol.* 2015;2:e000049. doi:10.1136/bmjgast-2015-000049
Our findings are similar to results from large randomised controlled trials of PEG-IFN+RBV treatment. However, the generalisability of these previous trials has been limited due to the paucity of HCV-4, which represented less than 41 patients or 3% of the total subjects randomised to treatment with PEG-IFN+RBV. In contrast, the current meta-analysis includes 899 HCV-4 patients from studies, which also provided comparison data for other treated genotype(s). To our knowledge, this is the first meta-analysis comparing virological response in HCV-4 to HCV-1 and HCV-2/3 patients treated with PEG-IFN+RBV. Subgroup analysis included only observational or non-randomised studies since no large RCTs with sufficient numbers of HCV-4, HCV-1 and/or HCV-2/3 patients have been performed. In the absence of any large RCTs comparing these genotypes, this meta-analysis provides the largest sample of HCV-4, HCV-1 and HCV-2/3 patients with a direct comparison of their SVR rates.

In the secondary analysis of treatment predictors, RVR rates were 39.3% in HCV-4, 24.8% in HCV-1 and 75.9% in HCV-2/3. Prior estimates of RVR in all genotypes have ranged widely: 15%-60% in HCV-4, 24%-73% in HCV-1 and 50%-78% in HCV-2/3. Prior estimates of RVR in all genotypes have ranged widely: 15%-60% in HCV-4, 24%-73% in HCV-1 and 50%-78% in HCV-2/3, which may be due in part to demographic or epidemiological factors as well as the distribution of advantageous IL28B phenotypes, which were not assessed by the studies included in this analysis. In direct comparison, RVR was favoured in HCV-2/3 over HCV-4, OR 4.85 (CI 3.40 to 6.94, p<0.001) and HCV-4 over HCV-1, OR 1.96 (CI 1.64 to 2.35, p<0.001), a finding previously reported in the current literature.

With both AASLD and EASL guidelines, EVR is especially important for response-guided therapy as failure to achieve EVR is used to recommend discontinuation of therapy at week 12 of therapy. In our study, overall EVR rates were 72.8% in HCV-4, 59.4% in HCV-1, and 91.4% in HCV-2/3. SVR rates in those who achieved EVR were 75.4% in HCV-4, 64% in HCV-1 and 85.2% in HCV-2/3. In contrast, SVR rates in those who did not reach EVR were 10% in HCV-4, 13.1% in HCV-1, and 22.3% in HCV-2/3. Failure to achieve EVR was a negative predictor of response to treatment for all genotypes.

As with HCV-1, lack of EVR is a good stopping rule for HCV-4 given the low SVR rate in those without EVR in the current meta-analysis and supports the societal recommendations that group HCV-4 with HCV-1. In addition, continuing therapy in HCV-4 patients who achieve EVR is also important as approximately three-quarters of HCV-4 patients treated with PEG-IFN+RBV achieved EVR and of those patients, three-quarters achieved SVR.

Although our meta-analysis is the first to quantitatively evaluate treatment predictors and outcomes in such a large population of patients with HCV-4, HCV-1, or HCV-2/3, this study was not without its limitations. Data on newer, all-oral regimens was not included. Additionally, only a small number of studies with a significant amount of heterogeneity were available for this analysis, which limited our ability to perform any additional subgroup analyses or detect publication bias. Our comprehensive literature search yielded only observational or non-randomised studies. Although randomised controlled trials are the reference standard, the studies included in
this analysis may be more generalisable to routine clinic settings of heterogeneous patient populations.

In summary, this meta-analysis of PEG-IFN-RBV treated patients, we observed a higher SVR rate in HCV2/3 (~70%) and comparable SVR rates in HCV-4 (~50%) and HCV-1 (~45%). As in HCV-1, failure to achieve EVR may be a good stopping rule for patients with HCV-4. Considering the lower SVR rates in HCV-4 and HCV-1, HCV-4 patients infected with these genotypes may significantly benefit from the recently FDA-approved triple therapies, where available. In more resource limited regions, given the higher rate of RVR (39%) and EVR in HCV-4 patients (73%) compared to HCV-1 patients (25% and 59%, respectively) and high SVR in those with EVR (75%), a response-guided approach using PEG IFN-RBV is probably still a reasonable option for the majority of patients. As hepatitis C treatment rapidly evolves, future trials may benefit from use of more diverse patient populations to improve the representation of less common genotypes.

Contributors MHN was guarantor of the article. BEY was involved in the study design, data collection, data analysis and interpretation of the manuscript. BZ and MHN were involved in the study design, data collection, data analysis and interpretation in the drafting of the manuscript. PV and CRW were involved in the data collection and critical review of the manuscript. DL and GAL were involved in the data interpretation and critical review of the manuscript. MHN was involved in the study design, data collection, data analysis and interpretation, and critical revision of the manuscript. All authors identified above have critically reviewed the paper and approve the final version of this paper, including the authorship statement.

Funding This study was funded in part by the NIH National Centre for Research Resources, TL1 training grants, TL1RR03197, to Nghia H. Nguyen and Bing Zhang.

Competing interests MHN has served as a consultant and an advisory board member for Gilead Sciences Inc., Bristol-Myers Squibb, Novartis, and Bayer.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board. Antwerp, Belgium. J Viral Hepat 1999;6:35–47.

2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558–67.

3. Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014;39:137–47.

4. Wise M, Bialek S, Finelli L, et al. Changing trends in hepatitis C-related mortality in the United States, 1995–2004. Hepatology 2008;47:1128–35.

5. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–74.

6. Hnatszyn HJ. Chronic hepatitis C and genotyping; the clinical significance of determining HCV genotypes. Antivir Ther 2005;10:1–11.

7. Kamal SM, Ahmed A, Mahmoud S, et al. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Liver Int 2013;37:593–9.

8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82.

9. Manns MP, McHughen JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65.

10. Abdo AA, Al-Abdal MN, Khalid SS, et al. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol Int 2013;7:593–8.

11. Afifi MT, El-Gohary A. Evaluation of the efficacy and safety of pegylated interferon (alpha)2a 160 mg (reiforider) and ribavirin combination in chronic HCV genotype 4 patients. J Gastroenterol Hepatol 2012;25(Suppl 2):A95.

12. Ahmed AM, Abboud OME, Mohammed NA, et al. Oxidative stress and the response to pegylated-interferon alfa2a plus ribavirin in chronic genotype 4 HCV hepatitis. EXCLI J 2013;12:605–15.

13. Al-Ashgar HI, Khan MQ, Helmy A, et al. Relationship of interferon-kDa expression in patients with various heterogeneities of hepatitis C virus genotype-4. Eur J Gastroenterol Hepatol 2013;25:404–10.

14. Al-Enzi SA, Ismail WA, Alsurayeai SA, et al. Peginterferon alfa-2b and ribavirin therapy in Kuwaiti patients with chronic hepatitis C virus infection. East Mediterr Health J 2011;17:669–78.

15. Antaki N, Bibert S, Kebbewar K, et al. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype-4. J Viral Hepat 2013;20:59–64.

16. Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012;56:527–32.

17. De Nicola S, Aghemo A, Rumi MG, et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012;55:336–42.

18. Derbala M, Amer A, Bener A, et al. Pegylated interferon-alpha2b/ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis C. J Hepatol 2005;12:380–5.

19. Derbala M, Rizk N, Sheibi F, et al. Interleukin-28B and hepatitis C virus genotype-2b treatment-induced clearance and liver fibrosis. World J Gastroenterol 2012;18:7003–8.

20. Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012;56:527–32.

21. Derbala M, Amer AM, Almoamari N, et al. Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment. J Viral Hepat 2011;18:269–262.

22. Derbala MF, Dweik NZ, Al-Kaabi SR, et al. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy. J Viral Hepat 2008;15:591–9.

23. El Khayat HR, Fouad YM, Ahmad EA, et al. Hepatitis C virus (genotype 4)-associated mixed cryoglobulinemia vasculitie effects of antiviral treatment. Hepatol Int 2012;6:606–12.

24. El Khayat HR, Fouad YM, El Amin H, et al. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response. Troy Gastroenterol 2012;3:112–17.

25. El Makhzangy H, Esmat G, Said M, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009;81:1576–83.

26. El Raziky M, Fathalah WF, EI-Akel WA, et al. The Effect of Peginterferon-Alpha-2a vs. Peginterferon Alphab-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study. Hepatol Mon 2013;13:e10069.

27. El-Shamy A, Shoji I, EI-Akel W, et al. NS5A sequence heterogeneity of hepatitis C virus genotype-4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol 2012;50:3886–92.

28. Eskander EF, Abd-Rabou AA, Yahya SM, et al. Does interferon and ribavirin combination therapy ameliorate growth hormone deficiency in HCV genotype-4 infected patients? Clin Biochem 2012;45:3–6.

29. Esmat G, Fathah SA. Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard(registered trademark) in Egyptian patients with chronic hepatitis C—genotype 4. Dig Liver Dis Suppl 2009;3:17–19. 

Yee BE, Nguyen NH, Zhang B, et al. BMJ Open Gastro 2015;2:e000049. doi:10.1136/bmjgast-2015-000049
30. Farag RE, Arafà MM, El-Etreby S, et al. Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients. *Arch Int Med* 2013;173:68–73.

31. Gad RR, Malés S, El Makhzangy H, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. *Liver Int* 2008;28:1112–19.

32. Hasan F, Aaker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. *J Gastroenterol* 2004;99:1733–7.

33. Ibrahim M, Gomaa W, Ibrahim Y, et al. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study. *J Gastroenterol Hepatol* 2010;25:441–7.

34. Kamal SM, El Kamary SS, Shaddad MR, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *Hepatology* 2012;56:461–9.

35. Karatapanis S, Dimitroulopoulos D, Papastergiou V, et al. Peginterferon alfa-2b genotype 4 response rate to pegylated interferon A2A or A2B and ribavirin is similar between caucasians and egyptian patients. *Eur J Intern Med* 2011;22(Suppl 1):S47.

36. Khairy M, Fouad R, Malrouk M, et al. The impact of interleukin 28 gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected Egyptian patients using data mining analysis. *Hepatol Mon* 2013;13:e10509.

37. Khattab M, Eslam M, Sharwaa MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. *J Gastroenterol* 2010;105:1970–7.

38. Khattab MA, Eslam M, Shatat M, et al. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4. *J Gastroenterol Hepatol* 2012;27:93–5.

39. Lopez-Alonso G, Agreda M, Devesa MJ, et al. Osteopontin gene polymorphisms as marker for prediction of response to treatment, a cohort Egyptian study of 4277 patients. *Clin Res Hepatol Gastroenterol* 2013;37:479–84.

40. Moreau P, Belghiti J, Barbier P, et al. Adipokines and insulin resistance in treated genotype 4 chronic hepatitis C patients with normal serum ALT. *Hepatol Mon* 2012;12:e6178.

41. Al Ali J, Owayed S, Al-Qabandi W, et al. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. *Ann Hepatol* 2010;9:516–60.

42. Al Ashgar HI, Khan MQ, Al-Ahdal M, et al. Peginterferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4 in Saudi Arabia: three years local experience in a university hospital. *Hepatol Mon* 2012;12:e6178.

43. Al Ali J, Siddique I, Varghese R, et al. Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT. *Ann Hepatol* 2012;11:86–93.

44. Alfaleh FZ, Alswat K, Helmy A, et al. The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy. *Liver Int* 2013;33:871–83.

45. Alswat K, Mamer A, Sabri F, et al. Neutropenia and viral load decline during treatment of hepatitis C virus genotype-4 patients: The paradox of treatment modification. *Hepatol Int* 2012;6:1894–9.

46. Alswat K, Al-Kaabi SR, El Dweik NZ, et al. Treatment of hepatitis C genotype 4 patients with Pegylated interferon-alpha-2a: impact of bilirubinemia and fibrosis stage. *World J Gastroenterol* 2006;12:5692–8.

47. Diago M, Hassanain T, Rodes J, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. *J Hepatol* 2010;52:497–502.

48. Shaheen Y, El-Shabab A, Fayez S, et al. Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4. *Cell Biochem Funct* 2013;31:620–5.

49. Shaker OG, Sadik NA. Polymorphisms in interleukin-10 and interleukin-28B gene of Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin therapy. *J Gastroenterol Hepatol* 2012;27:1842–9.

50. Saad Y, Ahmed A, Saleh DA, et al. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4. *Eur J Gastroenterol Hepatol* 2013;25:920–5.
74. el-Khattib AA, Abdelhakam SM, Ghoraba DM, et al. Outcome of antiviral therapy in Egyptian Hepatitis C Virus (HCV) genotype 4 patients with advanced liver fibrosis. *Eur J Intern Med* 2012;23:94–5.
75. Fathalla W, El-Akel W, Salama A, et al. The effect of peginterferon alpha-2a vs. Peginterferon alpha-2B in treatment of naive chronic HCV genotype-4 patients: A cohort Egyptian study. *Gastroenterology* 2012;142(5 Suppl. 1):S939.
76. Ferenci P, Tatari H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. *Gastroenterology* 2008;135:451–8.
77. Elsayed-elbatae H. Could vitamin D supplementation improve pegylated interferon plus ribavirin by IL28B gene variation in patients. *Inflamm* 2013;2013:392746.
78. Hamdi N, El-Akel W, El-Serafy M, et al. Transcriptional response of MxA, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response. *InterVirol* 2012;52:10–18.
79. Kamal S, Ghoraba D, Nabegh L, et al. Pegylated interferon alfa-2a vs pegylated interferon alfa-2b, plus ribavirin, for chronic hepatitis C genotype 4 patients: A randomized controlled trial. *Hepatology* 2009;50(Suppl 4):1025A–6A.
80. Khattab MA, Abdel-fattah ME, Eslam M, et al. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy. *J Clin Gastroenterol* 2010;44:707–12.
81. Legrand-Abraham F, Nicot F, Boulestin A, et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. *J Med Virol* 2005;77:86–9.
82. Mimidis K, Papadopoulos VP, Efthimiou I, et al. Hepatitis C virus survival curve analysis in naive patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. *J Gastroenterol Liver Dis* 2006;15:213–19.
83. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. *J Viral Hepat* 2010;17:917–24.
84. Shaker O, Ahmed A, Doss W, et al. MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients. *J Viral Hepat* 2010;17:794–9.
85. Shaker O, Bassioni H, El Raziky M, et al. Human leucocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4. *Mediators Inflamm* 2013;2013:392746.
86. Shaker OG, Eskander EF, Yahya SM, et al. Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients. *Clin Chir Ana* 2011;42:593–8.
87. Shiha G, Samir W, Seif S, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients with hepatitis C virus genotype 4. *Hepatology* 2012;56 (Suppl 1):1023A.
88. Taha A, Hasan M, El-Ray A, et al. Impact of cigarette smoking on the sustained viral response to treatment with pegylated interferon alpha-2a and ribavirin combination in male patients with chronic Hepatitis C Genotype 4. *Hepatol Int* 2012;6:187.
89. Velosa J, Stere F, Bana T, et al. Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice. *Hepatogastroenterology* 2011;58:1260–6.
90. Zayed N, Awad AB, El-Akel W, et al. The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C. *Clin Res Hepatol Gastroenterol* 2013;37:26–41.
91. Zayed N, Esmat G, Elakeel WA, et al. Therapeutic outcome in 6198 interferon-naive Egyptian patients with chronic hepatitis C genotype-4: A real experience. *Hepatology* 2012;56(Suppl 1):1016A.
92. Zekini AR, Hareem HA, Esmat GE, et al. Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. *J Viral Hepat* 2007;14:468–77.
93. European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol* 2014;60:392–420.
94. Sovaldi [package insert]. 2013. http://www.gilead.com/~/media/Files/medicines/liver-disease/sovaldi/sovaldi_pi.pdf
95. Harvoni [package insert]. 2014. http://www.gilead.com/~/media/Files/medicines/liver-disease/harvoni/harvoni_pi.pdf
96. Viekirak Pak [package insert]. 2014. http://www.ebivivie.com/content/dam/abbviecorp/us/desktop/contentrooms/downloads/ProductFactsheet_ViekirakPak_US.pdf
97. Organization WH. Guidelines for the screening, care, and treatment of persons with hepatitis C infection 2014. [cited 27 Sep 2014]. http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_ eng.pdf?ua=1
98. Rao P, Koshy A, Philip J, et al. Pegylated interferon alfa-2a plus ribavirin for treatment of chronic hepatitis C. *World J Hepatol* 2014;6:520–6.
99. Bonardi R, Tabone M, Manca A, et al. Short duration treatment in genotype 4 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. *Biomed Pharmacother* 2011;65:303–6.
100. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med* 2008;359:2205–17.
101. Yu JW, Wang GQ, Sun LJ, et al. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alfa-2a and ribavirin. *J Gastroenterol Hepatol* 2007;22:832–6.
102. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. *Hepatology* 2008;47:1884–93.
103. Dalgaard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. *Hepatology* 2008;47:35–42.
104. Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alfa-2a and ribavirin in 14 versus 24 weeks in patients with hepatitis C virus genotype 2/3 infection. *Hepatology* 2008;47:1837–45.
105. Shiftman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. *N Engl J Med* 2007;357:126–34.
106. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology* 2005;129:522–7.